Stomach & GEJ Cancer: Treatment Options & Specialist Care

This guide focuses on adenocarcinoma of the stomach and gastroesophageal junction, where the food pipe meets the stomach. Lymphoma, gastrointestinal stromal tumors and neuroendocrine cancers arising in the same area follow different pathways. A junction tumor's exact center and extent also affect whether the team uses a gastric or esophageal treatment approach.

Stage is the starting point, not the whole plan. A tumor at the stomach–esophagus junction may follow a different treatment sequence. Confirm the exact diagnosis and treatment goal before comparing hospitals or medicines.

Terms such as intestinal-type, diffuse-type, poorly cohesive and signet-ring cells describe microscopic appearance; they are not interchangeable with a treatment target. Grade describes differentiation, while stage describes extent. Selected patients with diffuse gastric cancer, younger onset or a relevant family history may need genetic counseling, including consideration of CDH1 or CTNNA1 testing.

These findings can overlap. A positive result does not rank treatments by itself, and different CLDN18.2 therapies do not necessarily use identical eligibility criteria.

TNM combines invasion through the stomach wall, regional lymph nodes and distant spread. Disease confined to superficial layers can be very different from a tumor extending into neighboring structures. Peritoneal spread and malignant peritoneal cytology have major implications even when the visible primary tumor appears removable.

Resectability asks whether all relevant disease can be removed safely with an appropriate operation. Fitness, expected stomach function and the likelihood of completing treatment matter alongside the stage number.

Peritoneal spread affects the lining of the abdomen and usually shifts the main plan toward systemic treatment. Ask whether an operation is intended to remove all disease or relieve a problem such as blockage. Assessment of cytoreductive surgery or HIPEC needs a specialist review of disease extent, fitness and evidence for the proposed approach.

Endoscopic removal or stomach surgery

Carefully selected very early cancers may qualify for endoscopic removal. Depth, ulceration, size, histology and the risk of lymph-node involvement determine suitability. More extensive resectable disease generally requires partial or total gastrectomy with appropriate lymph-node surgery, often with systemic treatment before and/or after the operation.

Plan the treatment before and after surgery

The current US durvalumab indication includes adults with resectable gastric or GEJ adenocarcinoma: durvalumab with FLOT chemotherapy before and after surgery, then durvalumab alone. FLOT combines fluorouracil, leucovorin, oxaliplatin and docetaxel. This is a defined perioperative regimen; it does not mean every early cancer requires immunotherapy. Other regional pathways use surgery followed by adjuvant chemotherapy.

Ask the team to explain the whole sequence, not just the next infusion or operation: why treatment starts at that point, what will be reassessed and how nutrition will be supported.

Systemic treatment aims to control disease and preserve function. The first plan should consider HER2, PD-L1, MMR/MSI and CLDN18.2 before suitable tissue is exhausted. Chemotherapy remains a backbone for many patients, with targeted or immune treatment added when the tumor features and clinical setting support it.

If the cancer is HER2-positive

Current US first-line options for HER2-positive unresectable locally advanced or metastatic gastric/GEJ adenocarcinoma also include zanidatamab with tislelizumab and fluoropyrimidine/platinum chemotherapy for IHC 3+ or IHC 2+/ISH+ disease, or zanidatamab with that chemotherapy without tislelizumab for IHC 3+ disease. The different HER2 thresholds matter; these are complete alternative regimens, not drugs to add indiscriminately to another HER2 combination.

If immunotherapy is being considered

PD-L1 requirements must be checked for the actual drug and region. For example, the current US nivolumab indication with fluoropyrimidine/platinum chemotherapy for advanced or metastatic gastric/GEJ cancer requires PD-L1 expression of at least 1, assessed under the label's selection guidance. Older broad descriptions without a PD-L1 condition may no longer match the current label.

If CLDN18.2 is positive and HER2 is negative

In the United States, zolbetuximab with fluoropyrimidine/platinum chemotherapy is approved as first-line treatment for adults with CLDN18.2-positive, HER2-negative, unresectable locally advanced or metastatic gastric/GEJ adenocarcinoma, using an FDA-approved test. Nausea, vomiting and infusion reactions require proactive management. CLDN18.2 positivity alone does not establish suitability.

Cadonilimab: another first-line immune combination to assess

Cadonilimab targets PD-1 and CTLA-4. China has approved it with fluoropyrimidine and platinum chemotherapy for first-line advanced gastric/GEJ adenocarcinoma; the gastric evidence discussed here is in HER2-negative disease. In the 610-patient COMPASSION-15 trial, median overall survival was 14.1 versus 11.1 months with chemotherapy alone. Immune and chemotherapy side effects require monitoring, and severe treatment-related events were more frequent with the combination. The trial does not establish superiority over another PD-1-plus-chemotherapy regimen.

Reassess what changes the next decision

Bring the names, dates, best response and reason for stopping every previous treatment. Depending on what has already been used, the next discussion may include a different chemotherapy, ramucirumab-based treatment, a HER2-directed option, cell therapy or a trial. Repeat tissue testing can help when a target may have changed. The choice also depends on eating, weight, organ function and how quickly the cancer is growing.

CT041 / satri-cel: CAR T-cell therapy for a defined later-line group

China has approved CT041, a CLDN18.2-directed CAR T-cell therapy, for CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma after at least two prior treatment lines have failed. It uses the patient’s own engineered T cells and follows a different pathway from ready-made antibody medicines.

In the randomized phase II CT041-ST-01 trial, 156 patients were assigned to satri-cel or physician-selected treatment. Median progression-free survival was 3.25 versus 1.77 months; this measures time before progression or death, not a cure rate or a personal survival prediction. Treatment needs specialist monitoring for effects including low blood counts, cytokine release syndrome and gastrointestinal complications.

What we arrange before cell treatment

Chirona arranges specialist assessment of the full CLDN18.2 and HER2 reports, previous treatment and fitness, then coordinates the treating center, cell collection, manufacturing, admission and follow-up. The team also plans how to control disease during manufacturing and what happens if the patient’s condition changes.

Fudan University Shanghai Cancer Center · Shanghai, China

Its dedicated gastric surgery service offers laparoscopic, robotic and selected function-preserving procedures. It is worth considering when you need to compare the extent of stomach removal, lymph-node surgery and the balance between cancer control and eating function.

Zhongshan Hospital, Fudan University · Shanghai, China

Its gastric cancer multidisciplinary program brings surgical and nonsurgical treatment into one plan, with work on preoperative treatment and response assessment. This is useful when the main question is whether to operate now, treat first or reassess after treatment.

Ruijin Hospital · Shanghai, China

Its gastrointestinal surgery service has an established focus on minimally invasive gastrointestinal tumor surgery. A review can clarify whether that approach fits the tumor and how the operation, recovery and other treatment should be coordinated.

MD Anderson Cancer Center · Houston, United States

Its gastrointestinal cancer teams combine surgery, medicines, radiation and molecular profiling, with clinical trial options. Consider a review when comparing a combined treatment plan, biomarker-directed drugs or research options after previous therapy.

Memorial Sloan Kettering Cancer Center · New York, United States

Its gastric surgeons use laparoscopic and robot-assisted approaches as well as different forms of gastrectomy. It is relevant when you want a detailed review of partial versus total removal, surgical suitability and what the operation means for recovery and eating.

• Upper endoscopy with biopsy confirms the tissue diagnosis. Adequate tissue is also needed for biomarker testing.
• CT assesses local extension and distant spread; endoscopic ultrasound can help clarify depth and regional nodes in selected cases.
• Staging laparoscopy with peritoneal washings may detect small deposits or cancer cells that scans miss, particularly when curative surgery is being considered in higher-risk disease.
• Blood counts, organ function, weight change and nutritional assessment establish how treatment can be delivered safely.

A scan showing no obvious metastasis does not always settle operability. Ask whether additional staging could change the plan before committing to a major operation.

Symptoms that need prompt attention

Early symptoms may be nonspecific: persistent upper abdominal discomfort, feeling full quickly, reduced appetite or fatigue from anemia. Progressive swallowing difficulty, unexplained weight loss or recurrent vomiting needs investigation. Vomiting blood, black stools with weakness, or inability to keep fluids down requires urgent assessment.

Nutrition support should start when intake or weight begins to decline. Small, frequent meals, individualized protein and energy intake, and help with nausea or swallowing can make treatment easier to complete. If ordinary eating is insufficient, a dietitian and clinical team can assess supplements or feeding support rather than relying on increasingly restrictive diets.

After gastrectomy, rapid passage of food can cause dumping symptoms such as cramping, diarrhea, dizziness or later low blood sugar. Iron, vitamin B12 and other deficiencies need follow-up; total gastrectomy generally requires ongoing B12 replacement. Persistent vomiting, dehydration, marked weight loss or new pain warrants review.

Follow-up checks recurrence when appropriate, treatment effects and nutritional recovery. The schedule depends on stage and the treatment received. For advanced cancer, scans, symptoms, weight and laboratory results are interpreted together; a plan that shrinks a tumor but makes eating impossible needs reassessment.

Bleeding, obstruction, pain and fluid accumulation can sometimes be relieved with endoscopic, radiotherapy, surgical or supportive measures alongside systemic therapy. Palliative care can support symptom control at any stage of serious illness; it does not require stopping cancer treatment.

Helicobacter pylori and future risk

Helicobacter pylori infection is an important risk factor, alongside smoking and certain inherited conditions. Eradication can reduce future risk in appropriate settings, but it does not replace treatment of an established cancer.

Send the reports you already have

• Endoscopy, pathology and operative reports, with the exact location and available tissue details.
• Original scans, laparoscopy findings and peritoneal cytology if performed.
• Complete HER2, PD-L1, MMR/MSI and CLDN18.2 reports, including methods and scores.
• Previous treatment dates and responses, weight trend, food intake and current symptoms.

Ask: Is the aim cure or disease control? Is additional peritoneal staging needed? Which biomarker changes the first choice? How will eating and weight be protected? If considering cellular therapy, what exactly must be confirmed before travel?